Interleukin 6: A biomarker for COVID-19 progression
- PMID: 35937954
- PMCID: PMC9343743
- DOI: 10.1016/j.matpr.2022.07.387
Interleukin 6: A biomarker for COVID-19 progression
Abstract
COVID-19 was discovered in China for the first time in December 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. Due to its rapid geographic expansion over the last three years, it has now become a global health issue. The infection is caused by SARS-CoV-2, which is obtained from a zoonotic source and transmitted directly or through contact. Following exposure, the immune system becomes hyperactive resulting in the production of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), a naturally occurring pleiotropic cytokine that plays a significant role in respiratory failure and multi-organ dysfunction. This massive inflammatory phenomenon is reminiscent of cytokine release syndrome (CRS) or "cytokine storm", which may be at the root of many severe complications. In fact, serum IL-6 levels are significantly high in patients with severe Covid-19 disease. The goal of treatment is to change the cytokine's concentration or activity. Interleukin-6 production could be inhibited, reducing inflammation and so serving as a therapeutic target. anti-interleukin-6 receptor monoclonal antibodies have been proven to reduce the severity of COVID-19 in clinical trials aimed at clarifying the function of immunoregulation. As a result, the Il-6 assay is a reliable predictor of morbidity and mortality at the time of infection diagnosis. The aim of our study is to highlight the role of interleukin 6 as biomarker of the COVID- 19 progression.
Keywords: Biomarker; COVID-19; Cytokine storm; Interleukin-6; Monoclonal antibodies; SARS-CoV-2.
Copyright © 2023 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the Fifth edition of the International Conference on Materials & Environmental Science.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Guan W., et al. China medical treatment expert group for Covid-19. Clin. Charact. Coronavirus Dis. 2019;382(18):1708–1720.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous